Cardiac POC Testing Devices Market Analysis & Forecast: 2026-2033

Cardiac POC testing devices Market Size and Share Analysis: 2026 - 2033

The global Cardiac POC testing devices Market size is projected to grow from USD 3,903.3 Mn in 2026 to USD 6,307.7 Mn by 2033, registering a compound annual growth rate (CAGR) of 7.1% during the forecast period (2026-2033). Market growth is primarily driven by the rising prevalence of cardiovascular diseases, increasing demand for rapid diagnostic solutions, growing adoption of point-of-care testing in emergency and critical care settings, and ongoing advancements in portable and high-sensitivity diagnostic technologies.

Key Takeaways from the Cardiac POC testing devices Market Report

• The cardiac markers test segment is expected to lead the market with a share of 78.4% in 2026 owing to the increasing demand for rapid and accurate biomarker-based diagnostic testing for acute cardiac conditions. According to the American Heart Association (AHA), cardiovascular diseases remain the leading cause of death globally, accounting for nearly 20.5 million deaths annually, which is significantly increasing the need for rapid cardiac diagnostic solutions.
• The hospitals segment is expected to dominate the global Cardiac POC testing devices Market with a share of 46.2% in 2026 owing to the growing number of emergency cardiovascular admissions, rising adoption of point-of-care diagnostics in intensive care units, and increasing hospital-based cardiac monitoring programs. According to WHO, approximately 17.9 million people die annually due to heart-related illnesses which accounts for about 32% of deaths globally, thus emphasizing the importance of having fast cardiac testing facilities in hospitals.
• North America is projected to lead the global market in terms of its share at 39.8%, driven by the increasing incidence rate of cardiovascular disorders, extensive adoption of innovative point-of-care diagnostic tools, favorable insurance coverages, and presence of major players in the industry. As per statistics from the Centers for Disease Control and Prevention (CDC), heart disease is still the number one killer in the US, causing almost 1 out of every 5 deaths, thereby fuelling the need for cardiac diagnostic testing tools that provide instant results.

Segmental Insights

To learn more about this report, Request Free Sample

Why is the Cardiac Markers Test Segment Dominating the Market?

Cardiac markers test is expected to dominate the market by holding the largest market share of around 78.4% in 2026. The growing need for biomarker tests for the diagnosis of acute heart diseases such as myocardial infarction, heart attack, and acute coronary syndrome, etc., through diagnostic testing is anticipated to drive the growth of the market. Cardiac Troponin Assays are currently the most common type of cardiac biomarker tests due to its precision and sensitivity.

In February 2025, Siemens Healthineers expanded its point-of-care cardiac biomarker testing portfolio with enhanced high-sensitivity troponin testing capabilities designed to support rapid emergency cardiac diagnosis and decentralized healthcare delivery.

Which End User Segment Dominates the Market?

To learn more about this report, Request Free Sample

Hospitals account for the largest market share of 46.2% because of the sophisticated emergency care infrastructure, presence of specialist cardiology departments, and rising use of point-of-care diagnostics in ICU settings and emergency departments. The segment’s growth is supported by the high volume of acute cardiovascular cases requiring rapid diagnosis and immediate clinical intervention.

The increasing trend of cardiovascular diseases along with emergency admission of patients suffering from heart conditions is expected to drive the market. As per the reports published by WHO, cardiovascular diseases contribute to about 17.9 million deaths every year globally, which account for almost 32% of all deaths.

Market Drivers

Rising Burden of Cardiovascular Diseases is Accelerating Demand for Cardiac PoC Testing

The growing incidences of cardiovascular disease in the world are playing an important role in the increasing demand for cardiac PoC test devices. Hospitals and emergency departments are increasingly adopting cardiac POC testing devices for rapid detection of acute cardiac conditions.

According to the World Heart Federation, more than 520 million people globally are currently living with cardiovascular diseases, while cardiovascular-related deaths continue to rise each year.

In March 2025, F. Hoffmann-La Roche Ltd. expanded its high-sensitivity cardiac troponin testing portfolio for point-of-care applications to support faster emergency cardiac assessment and improve early diagnosis of myocardial infarction in hospital and outpatient settings.

Advancements in Rapid Diagnostic Technologies are Transforming Cardiac PoC Testing

Advancements in portable analyzers, biosensors, and multiplex diagnostic platforms are improving the speed, accuracy, and portability of cardiac PoC testing devices. Modern point-of-care systems increasingly incorporate wireless connectivity, AI-assisted analytics, and compact handheld designs, allowing medical practitioners to conduct cardiac biomarkers tests even from places other than central labs.

Based on reports from the National Institutes of Health (NIH), the use of rapid high sensitivity cardiac troponin tests is known to cut down the amount of time required to diagnose acute coronary syndrome cases in emergency departments.

In September 2025, Abbott Laboratories introduced an upgraded portable cardiac biomarker analyzer featuring enhanced AI-enabled clinical decision support and faster turnaround time for emergency cardiovascular diagnostics.

Current Events and Their Impact on the Cardiac POC testing devices Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Cardiac POC testing devices Market Trends

• Rising adoption of high-sensitivity cardiac troponin assays is improving early diagnosis of myocardial infarction and accelerating demand for rapid point-of-care cardiac diagnostics in emergency care settings.
• Increasing integration of artificial intelligence and digital connectivity in cardiac PoC analyzers enhances clinical decision-making, improves workflow efficiency, and supports real-time patient monitoring across hospitals and ambulatory care centers.
• Growing preference for decentralized and near-patient testing is driving deployment of portable and handheld cardiac POC testing devices in remote healthcare facilities, emergency ambulances, and outpatient settings worldwide.
• Aging global populations and increasing prevalence of cardiovascular diseases continue to bolster demand for rapid cardiac diagnostic solutions.
• Increasing investments in emergency healthcare infrastructure and critical care services are supporting wider adoption of cardiac POC testing devices in hospitals and intensive care units globally. According to the American Hospital Association (AHA), hospitals continue to expand rapid diagnostic testing capabilities to improve emergency response efficiency and patient outcomes.

Regional Insights

To learn more about this report, Request Free Sample

North America Dominates owing to High Adoption of Advanced Cardiac PoC Diagnostic Technologies

North America is anticipated to hold a share of 39.8% of the market, attributed to factors such as high incidence rate of heart diseases, widespread use of advanced point-of-care diagnostic devices, favorable reimbursement structure, and presence of major companies operating in the market. The rising cases of heart emergencies and increasing demand for fast diagnosis procedures at various hospitals and ambulatory care centers are fueling the growth of the regional cardiac POC testing device market.

Cardiovascular diseases continue to be among the highest health burdens in the region. The Center for Disease Control and Prevention states that heart disease continues to be the number one killer in the United States, being responsible for about 697,000 deaths per year. Moreover, heart attacks affect more than 805,000 people yearly in America.

Asia Pacific Cardiac POC testing devices Market Trends

Asia-Pacific is expected to become the fastest growing regional market between 2026-2033 owing to the prevalence of cardiovascular diseases, rise in healthcare spending, and advanced emergency healthcare facilities. Increasing use of decentralized diagnostics and portable heart testing equipment by countries including China, India, and Japan is driving the growth of the region.

In February 2025, Siemens Healthineers launched the RAPID Point 500e Blood Gas System across select Southeast Asian markets including Singapore and Malaysia.

Rising Cardiovascular Disease Burden is Accelerating the Cardiac POC testing devices Market Demand in United States

The United States Cardiac POC testing devices Market has been witnessing strong growth owing to the rising incidences of cardiovascular disease, high instances of emergency cardiac admissions, and rising usage of rapid diagnostic tools. Rapid cardiac biomarker testing continues to witness strong adoption in the region due to the large number of cases related to myocardial infarctions, heart failure, and acute coronary syndromes.

In September 2025, Abbott Laboratories launched an upgraded portable cardiac point-of-care analyzer designed for emergency departments and intensive care units, featuring enhanced turnaround speed and AI-assisted interpretation capabilities.

Japan Cardiac POC testing devices Market Trends

The Japan Cardiac POC testing devices Market is estimated to have a significant growth rate during the forecast period due to the rapid aging of the population in Japan, higher incidences of cardiovascular diseases, and increased investment in innovative technologies. The population in Japan continues to be considered one of the oldest populations globally, with a considerable percentage being older than 65 years, thereby raising the cases of heart diseases, arrhythmias, and heart failure.

In May 2025, Sysmex Corporation announced the expansion of its cardiovascular diagnostic portfolio with next-generation rapid biomarker testing systems designed to improve emergency cardiac assessment and laboratory efficiency.

Who are the Major Companies in Cardiac POC testing devices Industry

Some of the major key players in Cardiac POC testing devices are Abbott Laboratories, BG Medicine Inc., Roche Diagnostics, Inc., Medtronic Inc., and Siemens Healthineers.

Key News

• In May 2025, Roche announced expansion of its near-patient care portfolio through commercialization of the LumiraDx system in Germany.
• In November 2025, Medtronic announced additional investments in digital cardiovascular care technologies focused on improving remote patient monitoring and accelerating emergency cardiac intervention workflows.

Market Report Scope

Analyst Opinion

• Cardiac POC testing devices are witnessing strong demand due to the rising global burden of cardiovascular diseases.
• Emergency departments and intensive care units are rapidly adopting point-of-care cardiac diagnostics because faster turnaround times can significantly improve patient survival rates during acute cardiac events such as myocardial infarction and heart failure.
• High-sensitivity cardiac troponin testing is becoming a major growth driver for the market. Advanced troponin assays provide highly accurate detection of cardiac injury within a shorter timeframe, helping clinicians make quicker treatment decisions and reduce unnecessary hospital admissions.
• The market is benefiting from the growing shift toward decentralized healthcare and near-patient testing. Portable analyzers and handheld biomarker testing systems are enabling hospitals, ambulatory care centers, and remote healthcare providers to conduct rapid cardiac assessments without relying solely on centralized laboratories.
• Artificial intelligence integration and digital connectivity are expected to reshape the future of cardiac PoC testing. AI-enabled analyzers can improve diagnostic accuracy, automate interpretation, and support real-time clinical decision-making in emergency settings.
• Asia Pacific is expected to emerge as a key growth engine due to rising healthcare investments, increasing prevalence of lifestyle-related cardiac disorders, and expanding adoption of rapid diagnostic technologies across emerging economies such as China and India.

Market Segmentation

• By Product Type (Revenue, USD Mn, 2021-2033)
  • Cardiac Markers Test
  • Analyzers
• By End User (Revenue, USD Mn, 2021-2033)
  • Research Laboratories
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Laboratories
  • Others
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Abbott Laboratories
  • BG Medicine Inc.
  • Roche Diagnostics, Inc.
  • Medtronic Inc.
  • Siemens Healthineers

Sources

Primary Research Interviews

• Cardiologists
• Emergency medicine physicians
• Critical care specialists
• Hospital administrators
• Point-of-care testing laboratory managers
• Diagnostic laboratory professionals
• Medical device distributors
• Cardiovascular diagnostic equipment manufacturers
• Key opinion leaders (KOLs) in cardiovascular diagnostics
• Healthcare technology consultants

Databases

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• Organisation for Economic Co-operation and Development (OECD)
• American Heart Association (AHA)
• World Heart Federation
• European Society of Cardiology (ESC)

Magazines                                         

• Cardiology Today
• Diagnostic and Interventional Cardiology
• Medical Device Network
• Healthcare IT News

Journals

• Journal of the American College of Cardiology (JACC)
• Circulation
• European Heart Journal
• Clinical Chemistry
• American Journal of Cardiology

Newspapers

• The New York Times
• The Wall Street Journal
• Financial Times
• The Guardian

Associations

• American College of Cardiology (ACC)
• American Heart Association (AHA)
• European Society of Cardiology (ESC)
• World Heart Federation
• Society for Cardiovascular Angiography & Interventions (SCAI)

Public Domain Sources

• Company Annual Reports and Investor Presentations
• Government Healthcare Ministry Publications
• Clinical Trial Registries such as ClinicalTrials.gov
• FDA Medical Device Safety and Approval Databases
• Healthcare Reimbursement and Policy Publications

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for Last 10 Years